Horizon Pharma Plc Stock Retained Earnings
HZNPDelisted Stock | USD 116.30 0.00 0.00% |
Horizon Pharma PLC fundamentals help investors to digest information that contributes to Horizon Pharma's financial success or failures. It also enables traders to predict the movement of Horizon Stock. The fundamental analysis module provides a way to measure Horizon Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Horizon Pharma stock.
Horizon |
Horizon Pharma PLC Company Retained Earnings Analysis
Horizon Pharma's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Horizon Pharma Retained Earnings | 590.01 M |
Most of Horizon Pharma's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Horizon Pharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Horizon Pharma PLC has a Retained Earnings of 590.01 M. This is 36.65% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The retained earnings for all United States stocks is 93.68% higher than that of the company.
Horizon Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Horizon Pharma's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Horizon Pharma could also be used in its relative valuation, which is a method of valuing Horizon Pharma by comparing valuation metrics of similar companies.Horizon Pharma is currently under evaluation in retained earnings category among related companies.
Horizon Fundamentals
Return On Equity | 0.0854 | |||
Return On Asset | 0.0444 | |||
Profit Margin | 0.12 % | |||
Operating Margin | 0.18 % | |||
Current Valuation | 26.87 B | |||
Shares Outstanding | 229 M | |||
Shares Owned By Insiders | 1.18 % | |||
Shares Owned By Institutions | 98.82 % | |||
Number Of Shares Shorted | 7.1 M | |||
Price To Earning | 32.55 X | |||
Price To Book | 5.10 X | |||
Price To Sales | 6.93 X | |||
Revenue | 3.63 B | |||
Gross Profit | 2.8 B | |||
EBITDA | 1.11 B | |||
Net Income | 521.48 M | |||
Cash And Equivalents | 2.13 B | |||
Cash Per Share | 9.40 X | |||
Total Debt | 2.56 B | |||
Debt To Equity | 0.53 % | |||
Current Ratio | 3.96 X | |||
Book Value Per Share | 23.20 X | |||
Cash Flow From Operations | 1.26 B | |||
Short Ratio | 2.04 X | |||
Earnings Per Share | 1.88 X | |||
Price To Earnings To Growth | 1.00 X | |||
Target Price | 116.5 | |||
Number Of Employees | 2.19 K | |||
Beta | 1.01 | |||
Market Capitalization | 26.63 B | |||
Total Asset | 9.11 B | |||
Retained Earnings | 590.01 M | |||
Working Capital | 2.7 B | |||
Current Asset | 1.11 B | |||
Current Liabilities | 357.55 M | |||
Z Score | 7.48 | |||
Net Asset | 9.11 B |
About Horizon Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Horizon Pharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Horizon Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Horizon Pharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |